I-131 MIBG is a drug that is used to treat neuroblastoma. It is a clear liquid, made of two materials: metaiodobenzylguanidine, or MIBG, and I-131, a radioactive material. The MIBG carries the radioactive I-131 specifically to the patients’ tumors, where it targets the cancer cells over many weeks.
MIBG is given slowly using an infusion pump like the one shown above. The pump sends the MIBG into the bloodstream using the patient’s central line. The process takes about two hours and is not painful. The patient’s blood pressure and heart rate will be checked every 15 minutes during the infusion.
Once the radioactive material enters the bloodstream, it travels to the cancer cells in the patient’s body. A significant amount of the radioactive material travels into the kidneys and is passed out of the body through the patient’s urine over several days. The patient will have a bladder catheter (Foley catheter) throughout most of their hospital stay. While most of the radiation passes out of the body through the urine, some of the radioactive material will leave the patient’s body through sweat, saliva, and feces.
The radiation leaving the patient’s body in the days following treatment is what makes MIBG so different from other cancer treatments. Because MIBG is radioactive, it is handled very carefully. We take many precautions to ensure your safety, and the safety of other patients and staff, while treating a patient with MIBG. To limit radiation exposure to others, you will be the primary caregiver for the patient, who will stay in a special room at the hospital until the radiation has gone down to a safe level. This usually takes 2 to 5 days from the time the MIBG is given.